CN112479982A - 一种手性吲哚-2,3-并八元碳环化合物的制备方法 - Google Patents
一种手性吲哚-2,3-并八元碳环化合物的制备方法 Download PDFInfo
- Publication number
- CN112479982A CN112479982A CN202011448322.4A CN202011448322A CN112479982A CN 112479982 A CN112479982 A CN 112479982A CN 202011448322 A CN202011448322 A CN 202011448322A CN 112479982 A CN112479982 A CN 112479982A
- Authority
- CN
- China
- Prior art keywords
- indole
- palladium
- chiral
- reaction
- silver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001717 carbocyclic compounds Chemical class 0.000 title claims abstract description 31
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 title claims description 33
- 238000002360 preparation method Methods 0.000 title claims description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 19
- 229910052763 palladium Inorganic materials 0.000 claims abstract description 14
- VHXADKWNENAESO-UHFFFAOYSA-N cyclooctene-1-carboxylic acid Chemical class OC(=O)C1=CCCCCCC1 VHXADKWNENAESO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003054 catalyst Substances 0.000 claims abstract description 8
- 239000003446 ligand Substances 0.000 claims abstract description 8
- 239000003960 organic solvent Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 75
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- 239000005457 ice water Substances 0.000 claims description 17
- 238000004440 column chromatography Methods 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 239000012074 organic phase Substances 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 239000003208 petroleum Substances 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000002390 rotary evaporation Methods 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 11
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 10
- CSIFGMFVGDBOQC-UHFFFAOYSA-N 3-iminobutanenitrile Chemical compound CC(=N)CC#N CSIFGMFVGDBOQC-UHFFFAOYSA-N 0.000 claims description 8
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 claims description 8
- 229910000161 silver phosphate Inorganic materials 0.000 claims description 8
- 229940019931 silver phosphate Drugs 0.000 claims description 8
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- -1 (S) -MeO-BIPHEP Chemical compound 0.000 claims description 6
- HGMLTMOEYCQDDR-UHFFFAOYSA-N [4-(5-diphenylphosphanyl-2,2-difluoro-1,3-benzodioxol-4-yl)-2,2-difluoro-1,3-benzodioxol-5-yl]-diphenylphosphane Chemical compound C=12OC(F)(F)OC2=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1C1=C2OC(F)(F)OC2=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 HGMLTMOEYCQDDR-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000012071 phase Substances 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 5
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 claims description 5
- 229940071536 silver acetate Drugs 0.000 claims description 5
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 claims description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910001958 silver carbonate Inorganic materials 0.000 claims description 4
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 claims description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 4
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- ZNORAFJUESSLTM-UHFFFAOYSA-N [4-[5-bis(3,5-ditert-butyl-4-methoxyphenyl)phosphanyl-1,3-benzodioxol-4-yl]-1,3-benzodioxol-5-yl]-bis(3,5-ditert-butyl-4-methoxyphenyl)phosphane Chemical compound C1=C(C(C)(C)C)C(OC)=C(C(C)(C)C)C=C1P(C=1C(=C2OCOC2=CC=1)C=1C(=CC=C2OCOC2=1)P(C=1C=C(C(OC)=C(C=1)C(C)(C)C)C(C)(C)C)C=1C=C(C(OC)=C(C=1)C(C)(C)C)C(C)(C)C)C1=CC(C(C)(C)C)=C(OC)C(C(C)(C)C)=C1 ZNORAFJUESSLTM-UHFFFAOYSA-N 0.000 claims description 2
- GDMCOFXEPNHXJT-UHFFFAOYSA-N [5-(6-diphenylphosphanyl-2,3-dihydro-1,4-benzodioxin-5-yl)-2,3-dihydro-1,4-benzodioxin-6-yl]-diphenylphosphane Chemical compound O1CCOC(C=2C=3C=4OCCOC=4C=CC=3P(C=3C=CC=CC=3)C=3C=CC=CC=3)=C1C=CC=2P(C=1C=CC=CC=1)C1=CC=CC=C1 GDMCOFXEPNHXJT-UHFFFAOYSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- TWKVUTXHANJYGH-UHFFFAOYSA-L allyl palladium chloride Chemical class Cl[Pd]CC=C.Cl[Pd]CC=C TWKVUTXHANJYGH-UHFFFAOYSA-L 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 2
- JKDRQYIYVJVOPF-FDGPNNRMSA-L palladium(ii) acetylacetonate Chemical compound [Pd+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O JKDRQYIYVJVOPF-FDGPNNRMSA-L 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 2
- 229910001494 silver tetrafluoroborate Inorganic materials 0.000 claims description 2
- UKSZBOKPHAQOMP-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1.C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 UKSZBOKPHAQOMP-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 claims 1
- 238000010626 work up procedure Methods 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 8
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 6
- 238000006254 arylation reaction Methods 0.000 abstract description 4
- 238000006317 isomerization reaction Methods 0.000 abstract description 4
- 150000002081 enamines Chemical class 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract description 3
- 238000010276 construction Methods 0.000 abstract description 2
- 125000001041 indolyl group Chemical group 0.000 abstract description 2
- 239000000758 substrate Substances 0.000 abstract description 2
- 125000001743 benzylic group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052709 silver Inorganic materials 0.000 abstract 1
- 239000004332 silver Substances 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 44
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 4
- JFFARAVOJMYATH-UHFFFAOYSA-N C1CCCCCC(C(=O)OC)=C1NC1=CC=CC=C1I Chemical class C1CCCCCC(C(=O)OC)=C1NC1=CC=CC=C1I JFFARAVOJMYATH-UHFFFAOYSA-N 0.000 description 4
- 238000006717 asymmetric allylation reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006352 cycloaddition reaction Methods 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- KARZVIJDVBTITL-UHFFFAOYSA-N 1-methyl-2-pent-4-enylindole Chemical class C1=CC=C2N(C)C(CCCC=C)=CC2=C1 KARZVIJDVBTITL-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000007036 catalytic synthesis reaction Methods 0.000 description 1
- CZKMPDNXOGQMFW-UHFFFAOYSA-N chloro(triethyl)germane Chemical compound CC[Ge](Cl)(CC)CC CZKMPDNXOGQMFW-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 150000008301 phosphite esters Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
本发明公开了一种手性吲哚‑2,3‑并八元碳环化合物的制备方法,它是通过钯催化2‑(2‑碘芳氨基)环辛‑1‑烯‑1‑羧酸酯衍生物通过烯胺异构化/分子内不对称芳基化反应合成手性吲哚‑2,3‑并八元碳环化合物的方法,具体为:以钯作为催化剂,通过配体和银盐的共同作用,在有机溶剂中,于室温‑100℃的温度下反应生成相应的手性吲哚‑2,3‑并八元碳环化合物。本发明以易制备的2‑(2‑碘芳氨基)环辛‑1‑烯‑1‑羧酸酯衍生物作为原料,通过一步构建一个环和一根化学键并建立吲哚C2苄位上的手性中心,实现了手性吲哚‑2,3‑并八元碳环化合物快速构建。该反应条件温和、操作简便,具有反应原料易得、底物适用性广、产率与对映选择性优异和目标产物易分离等优点。
Description
技术领域
本发明属于不对称催化合成技术领域,涉及一种手性吲哚-2,3-并八元碳环化合物的制备方法,更具体地说,涉及一种通过钯催化2-(2-碘芳氨基)环辛-1-烯-1-羧酸酯通过烯烃异构化/分子内不对称芳基化反应合成手性吲哚-2,3-并八元碳环化合物的方法。
背景技术
吲哚2,3-并环结构的化合物普遍存在于天然产物和生物活性分子中,并在医药、农药、染料、生物等领域受到广泛关注,其结构如式(1)所示的几个化合物,一直是有机合成化学家们的研究对象之一。近年来,利用不同的反应策略实现手性吲哚2,3-并环化合物的合成研究已经有了较多的文献报道。其中,利用过渡金属或有机小分子催化的支链取代吲哚的不对称环加成、不对称芳氢化、或者不对称烯丙基化反应,是实现手性2,3-并环吲哚合成普遍方法。例如,利用不对称环加成的策略,实现脯氨醇催化2-烯基吲哚和反式肉桂醛的不对称Diels-Alder反应;利用不对称芳氢化反应的策略,实现光学纯铂-BIPHEP络合物催化1-甲基-2-(4-戊烯基)-吲哚衍生物的不对称芳氢化反应;利用不对称烯丙基化反应策略,实现醋酸钯-手性亚磷酸酯催化的不对称烯丙基烷基化反应。
不过遗憾的是,文献中一般以支链取代吲哚为底物,利用吲哚环的亲核性,通过不对称氢化、不对称环加成、不对称烯丙基化等策略,实现吲哚-2,3-并环化合物的构建,且所得到的手性吲哚并环衍生物多为吲哚-2,3-并六元环或-并五元环化合物,而利用类似的策略尚不能实现手性吲哚-2,3-并八元环的合成。
发明内容
针对现有技术中存在的上述问题,本发明的目的在于提供一种手性吲哚-2,3-并八元碳环化合物的制备方法,它利用容易制备的反应原料,通过钯催化烯胺异构化/分子内不对称芳基化反应过程,一步高效合成含C2苄位手性中心的手性吲哚-2,3-并八元碳环化合物。
所述的一种手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于以式(1)所示的2-(2-碘芳氨基)环辛-1-烯-1-羧酸酯为原料,在钯催化剂存在下,通过配体和银盐的共同作用,在有机溶剂中,于室温-100℃温度下进行反应,反应结束后经后处理得式(2)所示的手性吲哚-2,3-并八元碳环化合物,其反应通式如下:
式中:R1选自烷基、烷氧基或卤素中的一种;R2为烷基。
所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于R1、R2中的烷基选自C1~C10直链或支链的烷烃;R1中的烷氧基选自C1~C10直链或支链的烷氧基;R1中的卤素选自氟、氯或溴中的一种或两种。
所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于有机溶剂选自四氢呋喃、1,4-二氧六环、乙醚、乙二醇二甲醚、甲苯、间二甲苯、二氯甲烷、二氯乙烷、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N-甲基吡咯烷酮,有机溶剂的体积用量与2-(2-碘芳氨基)环辛-1-烯-1-羧酸酯衍生物的物质的量比为1~100:1,体积单位为毫升,物质的量单位为毫摩尔。
所述手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于钯催化剂选自双(二亚苄基丙酮)钯、三(二亚苄基丙酮)二钯、醋酸钯、烯丙基氯化钯二聚物、二乙腈二氯化钯、氯化钯、碘化钯、乙酰丙酮钯中的任意一种。
所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于配体选自(S)-BINAP、(S)-SegPhos、(S)-SynPhos、(S)-MeO-BIPHEP、(S)-DTBM-Segphos、(S)-SDP、(S)-DiFluorPhos的任意一种。
所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于银盐选自磷酸银、碳酸银、醋酸银、三氟甲磺酸银、四氟硼酸银、硝酸银的任意一种。
所述手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于2-(2-碘芳氨基)环辛-1-烯-1-羧酸酯和钯催化剂、配体、银盐的摩尔比为1:0.1~0.4:0.1~0.4:1~5。
所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于反应温度为40-80℃,反应时间为0.1-72h,优选为5h。
所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于后处理步骤为:反应结束后,在冰浴条件下缓慢滴加乙酸及冰水混合液直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后经柱层析分离得到目标产物,柱层析的流动相为体积比20~100:1的石油醚和乙酸乙酯混合物。
所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于于乙酸及冰水混合液中,乙酸及冰水的体积比为1:10-10:1,滴加速度为10-50滴/分钟。
通过采用上述技术,与现有技术相比,本发明的有益效果如下:
本发明通过以2-(2-碘芳氨基)环辛-1-烯-1-羧酸酯为原料,在钯催化剂、配体和银盐等的共同作用下,通过钯催化2-(2-碘芳氨基)环辛-1-烯-1-羧酸酯衍生物通过烯胺异构化/分子内不对称芳基化反应,一步高效合成手性吲哚-2,3-并八元碳环化合物,该反应原料简单易得、操作简便、条件温和,具有官能团容忍性好、底物普适性广、产率高、对映选择性高等优点。
具体实施方式
下面结合具体实施例对本发明作进一步描述,但本发明的保护范围并不仅限于此;
实施例1:
在反应管中依次加入2-(2-碘苯基氨基)环辛-1-烯-1-甲酸甲酯衍生物1a(77.0mg,0.2mmol),二乙腈二氯化钯(5.2mg,10mol%),(S)-DifluorPhos(16.4mg,12mol%),磷酸银(83.6mg,2equiv.),四氢呋喃(2.0mL,0.1M),反应混合物在40℃下反应4h,反应结束后,在冰浴条件下缓慢滴加乙酸以及冰水的2/1混合物,速度为40滴/分钟直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后采用柱层析分离的方法(石油醚:乙酸乙酯=100:1)分离得到目标产物化合物1,产率93%。
The er was determined to be 86/14 by HPLC.[Daicel Chiralpak C3 column(25cm×0.46cm ID),nhexane/iPrOH=90/10,1.0mL/min,254nm;tminor=8.6min,tmajor=9.5min].1H NMR(500MHz,CDCl3)δ8.93(s,1H),7.52(d,J=7.8Hz,1H),7.33(d,J=8.0Hz,1H),7.16-7.11(m,1H),7.11-7.05(m,1H),4.12(dd,J=12.4,4.8Hz,1H),3.79(s,3H),3.08(ddd,J=14.7,4.7,3.6Hz,1H),2.64-2.51(m,1H),2.09-1.97(m,1H),1.89(tt,J=13.2,4.5Hz,2H),1.67-1.55(m,2H),1.54-1.45(m,1H),1.39-1.31(m,1H),1.12-1.01(m,1H);13CNMR(125MHz,CDCl3)δ175.5,135.4,130.4,127.5,121.3,119.0,117.9,113.6,110.8,52.2,41.1,35.1,31.1,26.5,25.0,23.1.HRMS m/z(ESI+):Calculated for C16H19NNaO2([M+Na]+):280.1308 Found:280.1301.
实施例2:
在反应管中依次加入2-(2-碘苯基氨基)环辛-1-烯-1-甲酸甲酯衍生物1a(77.0mg,0.2mmol),二乙腈二氯化钯(5.2mg,10mol%),(S)-DifluorPhos(16.4mg,12mol%),磷酸银(83.6mg,2equiv.),四氢呋喃(10.0mL,0.02M),反应混合物在40℃下反应4h,反应结束后,在冰浴条件下缓慢滴加乙酸以及冰水的10/1混合物,速度为10滴/分钟直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后采用柱层析分离的方法(石油醚:乙酸乙酯=100:1)分离得到目标产物化合物1,产率83%。
The er was determined to be 82/18 by HPLC.[Daicel Chiralpak C3 column(25cm×0.46cm ID),nhexane/iPrOH=90/10,1.0mL/min,254nm;tminor=8.6min,tmajor=9.5min].1H NMR(500MHz,CDCl3)δ8.93(s,1H),7.52(d,J=7.8Hz,1H),7.33(d,J=8.0Hz,1H),7.16-7.11(m,1H),7.11-7.05(m,1H),4.12(dd,J=12.4,4.8Hz,1H),3.79(s,3H),3.08(ddd,J=14.7,4.7,3.6Hz,1H),2.64-2.51(m,1H),2.09-1.97(m,1H),1.89(tt,J=13.2,4.5Hz,2H),1.67-1.55(m,2H),1.54-1.45(m,1H),1.39-1.31(m,1H),1.12-1.01(m,1H);13CNMR(125MHz,CDCl3)δ175.5,135.4,130.4,127.5,121.3,119.0,117.9,113.6,110.8,52.2,41.1,35.1,31.1,26.5,25.0,23.1.HRMS m/z(ESI+):Calculated for C16H19NNaO2([M+Na]+):280.1308 Found:280.1301.
实施例3:
在反应管中依次加入2-(2-碘苯基氨基)环辛-1-烯-1-甲酸甲酯衍生物2a(84.0mg,0.2mmol),双(二亚苄基丙酮)钯(23.2mg,20mol%),(S)-BINAP(30.2mg,24mol%),碳酸银(25.5mg,1equiv.),甲苯(20mL,0.01M),反应混合物在40℃下反应1h,反应结束后,在冰浴条件下缓慢滴加乙酸以及冰水的5/1混合物,速度为20滴/分钟直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后采用柱层析分离的方法(石油醚:乙酸乙酯=100:1)分离得到目标产物化合物2,产率72%。
The er was determined to be 80/20 by HPLC.[Daicel Chiralpak AD-Hcolumn(25cm×0.46cm ID),nhexane/iPrOH=90/10,1.0mL/min,254nm;tminor=9.0min,tmajor=15.6min].1H NMR(500MHz,CDCl3)δ9.05(s,1H),7.46(d,J=1.9Hz,1H),7.23(d,J=9.4Hz,1H),7.07(dd,J=8.5,2.0Hz,1H),4.09(dd,J=12.4,4.8Hz,1H),3.79(s,3H),3.04-2.93(m,1H),2.59-2.47(m,1H),2.09-1.98(m,1H),1.94-1.81(m,2H),1.66-1.55(m,2H),1.45(ddd,J=15.2,8.0,2.6Hz,1H),1.34(ddd,J=18.6,12.6,2.5Hz,1H),1.10-0.94(m,1H);13C NMR(125MHz,CDCl3)δ175.3,133.7,132.1,128.5,124.7,121.4,117.4,113.4,111.8,52.3,40.9,35.2,31.0,26.4,25.0,23.0.HRMS m/z(ESI-):Calculated forC16H17ClNO2([M-H]-):290.0953,Found:290.0956.
实施例4:
在反应管中依次加入2-(2-碘苯基氨基)环辛-1-烯-1-甲酸甲酯衍生物2a(84.0mg,0.2mmol),双(二亚苄基丙酮)钯(11.6mg,10mol%),(S)-BINAP(15.1mg,12mol%),碳酸银(51mg,2equiv.),四氢呋喃(2.0mL,0.1M),反应混合物在40℃下反应1h,反应结束后,在冰浴条件下缓慢滴加乙酸以及冰水的1/10混合物,速度为50滴/分钟直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后采用柱层析分离的方法(石油醚:乙酸乙酯=100:1)分离得到目标产物化合物2,产率75%。
The er was determined to be 84/16 by HPLC.[Daicel Chiralpak AD-Hcolumn(25cm×0.46cm ID),nhexane/iPrOH=90/10,1.0mL/min,254nm;tminor=9.0min,tmajor=15.6min].1H NMR(500MHz,CDCl3)δ9.05(s,1H),7.46(d,J=1.9Hz,1H),7.23(d,J=9.4Hz,1H),7.07(dd,J=8.5,2.0Hz,1H),4.09(dd,J=12.4,4.8Hz,1H),3.79(s,3H),3.04-2.93(m,1H),2.59-2.47(m,1H),2.09-1.98(m,1H),1.94-1.81(m,2H),1.66-1.55(m,2H),1.45(ddd,J=15.2,8.0,2.6Hz,1H),1.34(ddd,J=18.6,12.6,2.5Hz,1H),1.10-0.94(m,1H);13C NMR(125MHz,CDCl3)δ175.3,133.7,132.1,128.5,124.7,121.4,117.4,113.4,111.8,52.3,40.9,35.2,31.0,26.4,25.0,23.0.HRMS m/z(ESI-):Calculated forC16H17ClNO2([M-H]-):290.0953,Found:290.0956.
实施例5:
在反应管中依次加入2-(2-碘苯基氨基)环辛-1-烯-1-甲酸甲酯衍生物3a(80.1mg,0.2mmol),二乙腈二氯化钯(20.8mg,40mol%),(S)-SegPhos(34.8mg,48mol%),磷酸银(83.6mg,2equiv.),二氯甲烷(10mL,0.02M),反应混合物在40℃下反应5h,反应结束后,反应结束后,在冰浴条件下缓慢滴加乙酸以及冰水的2/1混合物,速度为40滴/分钟直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后采用柱层析分离的方法(石油醚:乙酸乙酯=100:1)分离得到目标产物化合物3,产率70%。
The er was determined to be 78/22 by HPLC.[Daicel Chiralpak AD-Hcolumn(25cm×0.46cm ID),nhexane/iPrOH=90/10,1.0mL/min,254nm;tminor=9.0min,tmajor=15.6min].1H NMR(500MHz,CDCl3)δ8.75(s,1H),7.22(s,1H),7.14(d,J=8.6Hz,1H),6.91-6.83(dd,J=8.1,0.6Hz,1H),4.02(dd,J=12.3,4.8Hz,1H),3.70(s,3H),3.03-2.91(m,1H),2.53-2.42(m,1H),2.37(s,3H),1.94(ddd,J=11.4,7.9,4.4Hz,1H),1.80(ddd,J=12.8,9.0,4.9Hz,2H),1.60-1.47(m,2H),1.40(td,J=12.8,6.6Hz,1H),1.33-1.20(m,1H),0.98(ddd,J=17.4,11.0,7.1Hz,1H);13C NMR(125MHz,CDCl3)δ175.5,133.7,130.5,128.1,127.6,122.8,117.6,113.1,110.5,52.1,41.1,35.1,31.1,26.5,25.0,23.1,21.5.HRMS m/z(ESI+):Calculated for C17H21NNaO2([M+Na]+):294.1465,Found:294.1462.
实施例6:
在反应管中依次加入2-(2-碘苯基氨基)环辛-1-烯-1-甲酸甲酯衍生物3a(80.1mg,0.2mmol),二乙腈二氯化钯(5.2mg,10mol%),(S)-SegPhos(7.3mg,12mol%),磷酸银(83.6mg,2equiv.),四氢呋喃(2.0mL,0.1M),反应混合物在40℃下反应5h,反应结束后,在冰浴条件下缓慢滴加乙酸以及冰水的1/1混合物,速度为45滴/分钟直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后采用柱层析分离的方法(石油醚:乙酸乙酯=100:1)分离得到目标产物化合物3,产率74%。
The er was determined to be 84/16 by HPLC.[Daicel Chiralpak AD-Hcolumn(25cm×0.46cm ID),nhexane/iPrOH=90/10,1.0mL/min,254nm;tminor=9.0min,tmajor=15.6min].1H NMR(500MHz,CDCl3)δ8.75(s,1H),7.22(s,1H),7.14(d,J=8.6Hz,1H),6.91-6.83(dd,J=8.1,0.6Hz,1H),4.02(dd,J=12.3,4.8Hz,1H),3.70(s,3H),3.03-2.91(m,1H),2.53-2.42(m,1H),2.37(s,3H),1.94(ddd,J=11.4,7.9,4.4Hz,1H),1.80(ddd,J=12.8,9.0,4.9Hz,2H),1.60-1.47(m,2H),1.40(td,J=12.8,6.6Hz,1H),1.33-1.20(m,1H),0.98(ddd,J=17.4,11.0,7.1Hz,1H);13C NMR(125MHz,CDCl3)δ175.5,133.7,130.5,128.1,127.6,122.8,117.6,113.1,110.5,52.1,41.1,35.1,31.1,26.5,25.0,23.1,21.5.HRMS m/z(ESI+):Calculated for C17H21NNaO2([M+Na]+):294.1465,Found:294.1462.
实施例7:
在反应管中依次加入2-(2-碘苯基氨基)环辛-1-烯-1-甲酸甲酯衍生物4a(83.0mg,0.2mmol),双(二亚苄基丙酮)(11.6mg,10mol%),(S)-SDP(7.1mg,12mol%),醋酸银(32.1mg,2equiv.),甲苯(0.2mL,1M),反应混合物在60℃下反应10h,反应结束后,在冰浴条件下缓慢滴加乙酸以及冰水的2/1混合物,速度为40滴/分钟直至固体完全溶解,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后采用柱层析分离的方法(石油醚:乙酸乙酯=100:1)分离得到目标产物化合物4,产率75%。
The er was determined to be 77/23 by HPLC.[Daicel Chiralpak AD-Hcolumn(25cm×0.46cm ID),nhexane/iPrOH=80/20,0.7mL/min,254nm;tminor=13.3min,tmajor=20.7min].1H NMR(500MHz,CDCl3)δ8.81(s,1H),7.20(d,J=8.6Hz,1H),6.95(d,J=2.1Hz,1H),6.78(dd,J=8.7,2.4Hz,1H),4.07(dd,J=12.3,4.8Hz,1H),3.84(s,3H),3.76(s,3H),3.07-2.88(m,1H),2.65-2.46(m,1H),2.00(tt,J=10.9,4.0Hz,1H),1.87(ddd,J=16.9,10.5,6.8Hz,2H),1.65-1.55(m,2H),1.47(td,J=12.7,6.6Hz,1H),1.38-1.26(m,1H),1.13-1.00(m,1H);13CNMR(125MHz,CDCl3)δ175.4,153.8,131.3,130.6,127.8,113.3,111.4,111.1,100.0,55.8,52.1,41.1,35.1,31.0,26.5,25.0,23.1.HRMS m/z(ESI+):Calculated for C17H22NO3([M+H]+):288.1594,Found:288.1604.
实施例8:
在反应管中依次加入2-(2-碘苯基氨基)环辛-1-烯-1-甲酸甲酯衍生物4a(83.0mg,0.2mmol),双(二亚苄基丙酮)(11.6mg,10mol%),(S)-SDP(7.1mg,12mol%),醋酸银(32.1mg,2equiv.),甲苯(2.0mL,0.1M),反应混合物在60℃下反应10h,反应结束后,在冰浴条件下缓慢滴加乙酸以及冰水的2/1混合物,速度为40滴/分钟直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后采用柱层析分离的方法(石油醚:乙酸乙酯=100:1)分离得到目标产物化合物4,产率81%。
The er was determined to be 80/20 by HPLC.[Daicel Chiralpak AD-Hcolumn(25cm×0.46cm ID),nhexane/iPrOH=80/20,0.7mL/min,254nm;tminor=13.3min,tmajor=20.7min].1H NMR(500MHz,CDCl3)δ8.81(s,1H),7.20(d,J=8.6Hz,1H),6.95(d,J=2.1Hz,1H),6.78(dd,J=8.7,2.4Hz,1H),4.07(dd,J=12.3,4.8Hz,1H),3.84(s,3H),3.76(s,3H),3.07-2.88(m,1H),2.65-2.46(m,1H),2.00(tt,J=10.9,4.0Hz,1H),1.87(ddd,J=16.9,10.5,6.8Hz,2H),1.65-1.55(m,2H),1.47(td,J=12.7,6.6Hz,1H),1.38-1.26(m,1H),1.13-1.00(m,1H);13CNMR(125MHz,CDCl3)δ175.4,153.8,131.3,130.6,127.8,113.3,111.4,111.1,100.0,55.8,52.1,41.1,35.1,31.0,26.5,25.0,23.1.HRMS m/z(ESI+):Calculated for C17H22NO3([M+H]+):288.1594,Found:288.1604.
实施例9:
在反应管中依次加入2-(2-碘苯基氨基)环辛-1-烯-1-甲酸甲酯衍生物5a(87.4mg,0.2mmol),二乙腈二氯化钯(5.2mg,10mol%),(S)-DiFluorPhos(16.4mg,12mol%),磷酸银(83.6mg,2eq.),N,N-二甲基甲酰胺(0.5mL,0.2M),反应混合物在80℃下反应5h,反应结束后,在冰浴条件下缓慢滴加乙酸以及冰水的2/1混合物,速度为40滴/分钟直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后采用柱层析分离的方法(石油醚:乙酸乙酯=100:1)分离得到目标产物化合物5,产率77%。
The er was determined to be 87/13 by HPLC.[Daicel Chiralpak AD-Hcolumn(25cm×0.46cm ID),nhexane/iPrOH=90/10,0.8mL/min,254nm;tminor=5.7min,tmajor=6.4min].1H NMR(500MHz,CDCl3)δ9.20(s,1H),7.25(d,J=1.6Hz,1H),6.86(dd,J=10.6,1.7Hz,1H),4.09(dd,J=12.4,4.8Hz,1H),3.81(s,3H),3.01-2.88(m,1H),2.59-2.47(m,1H),2.12-2.03(m,1H),1.97-1.81(m,2H),1.68-1.56(m,2H),1.51-1.40(m,1H),1.40-1.31(m,1H),1.09-0.96(m,1H);13C NMR(125MHz,CDCl3)δ175.0,149.7,147.7,132.9,131.3(d,J=6.2Hz),124.0(d,J=8.6Hz),122.1(d,J=12.8Hz),114.3(d,J=2.1Hz),113.5(d,J=3.4Hz),107.5(d,J=20.2Hz),52.4,41.0,35.3,30.9,26.4,25.0,23.2.HRMS m/z(ESI-):Calculated for C16H16ClFNO2([M-H]-):308.0859,Found:308.0858.
实施例10:
在反应管中依次加入2-(2-碘苯基氨基)环辛-1-烯-1-甲酸甲酯衍生物5a(87.4mg,0.2mmol),二乙腈二氯化钯(5.2mg,10mol%),(S)-DiFluorPhos(16.4mg,12mol%),磷酸银(83.6mg,2eq.),四氢呋喃(2.0mL,0.1M),反应混合物在80℃下反应5h,反应结束后,在冰浴条件下缓慢滴加乙酸以及冰水的2/1混合物,速度为40滴/分钟直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后采用柱层析分离的方法(石油醚:乙酸乙酯=100:1)分离得到目标产物化合物5,产率83%。
The er was determined to be 87/13 by HPLC.[Daicel Chiralpak AD-Hcolumn(25cm×0.46cm ID),nhexane/iPrOH=90/10,0.8mL/min,254nm;tminor=5.7min,tmajor=6.4min].1H NMR(500MHz,CDCl3)δ9.20(s,1H),7.25(d,J=1.6Hz,1H),6.86(dd,J=10.6,1.7Hz,1H),4.09(dd,J=12.4,4.8Hz,1H),3.81(s,3H),3.01-2.88(m,1H),2.59-2.47(m,1H),2.12-2.03(m,1H),1.97-1.81(m,2H),1.68-1.56(m,2H),1.51-1.40(m,1H),1.40-1.31(m,1H),1.09-0.96(m,1H);13C NMR(125MHz,CDCl3)δ175.0,149.7,147.7,132.9,131.3(d,J=6.2Hz),124.0(d,J=8.6Hz),122.1(d,J=12.8Hz),114.3(d,J=2.1Hz),113.5(d,J=3.4Hz),107.5(d,J=20.2Hz),52.4,41.0,35.3,30.9,26.4,25.0,23.2.HRMS m/z(ESI-):Calculated for C16H16ClFNO2([M-H]-):308.0859,Found:308.0858.
实施例11:
在反应管中依次加入2-(2-碘苯基氨基)环辛-1-烯-1-甲酸甲酯衍生物6a(80.6mg,0.2mmol),双(二亚苄基丙酮)钯(11.6mg,10mol%),(S)-BINAP(15.1mg,12mol%),醋酸银(32.1mg,2equiv.),二氯甲烷(2.0mL,0.1M),反应混合物在100℃下反应10h,反应结束后,在冰浴条件下缓慢滴加乙酸以及冰水的2/1混合物,速度为40滴/分钟直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后采用柱层析分离的方法(石油醚:乙酸乙酯=100:1)分离得到目标产物化合物6,产率81%。
The er was determined to be 79/21 by HPLC.[Daicel Chiralpak OD-Hcolumn(25cm×0.46cm ID),nhexane/iPrOH=90/10,0.7mL/min,254nm;tmajor=5.9min,tminor=9.5min].1H NMR(500MHz,CDCl3)δ9.10(s,1H),7.27(d,J=7.9Hz,1H),6.97(td,J=7.9,4.7Hz,1H),6.84(dd,J=11.2,7.8Hz,1H),4.11(dd,J=12.4,4.8Hz,1H),3.80(s,3H),3.12-2.98(m,1H),2.65-2.51(m,1H),2.12-2.00(m,1H),1.90(tt,J=13.0,4.6Hz,2H),1.71-1.57(m,2H),1.48(tdd,J=10.0,6.4,3.5Hz,1H),1.41-1.31(m,1H),1.05(tdd,J=13.0,8.7,4.1Hz,1H);13C NMR(125MHz,CDCl3)δ175.2,149.5(d,J=243.6Hz),131.4,131.3(d,J=5.6Hz),123.6(d,J=12.8Hz),119.2(d,J=6.2Hz),114.5(d,J=2.0Hz),113.7(d,J=3.2Hz),106.3(d,J=16.3Hz),52.3,41.1,35.2,31.1,26.5,25.1,23.3.HRMS m/z(ESI-):Calculated for C16H17FNO2([M-H]-):274.1249,Found:274.1244.
实施例1~11涉及具体C2苄位手性的稠环1-H吲哚类化合物的合成方法对应的实验结果列于表1:
表1 铜催化合成吲哚啉酮反应结果[a]
[a]反应条件见实施例;[b]分离收率。
以上所述仅为本发明的几种具体实施例,其描述较为具体和详细,但本发明的保护范围并不局限于此。任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到的变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所附权利要求为准。
Claims (10)
2.根据权利要求1所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于R1、R2中的烷基选自C1~C10直链或支链的烷烃;R1中的烷氧基选自C1~C10直链或支链的烷氧基;R1中的卤素选自氟、氯或溴中的一种或两种。
3.根据权利要求1所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于有机溶剂选自四氢呋喃、1,4-二氧六环、乙醚、乙二醇二甲醚、甲苯、间二甲苯、二氯甲烷、二氯乙烷、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N-甲基吡咯烷酮,有机溶剂的体积用量与2-(2-碘芳氨基)环辛-1-烯-1-羧酸酯衍生物的物质的量比为1~100:1,体积单位为毫升,物质的量单位为毫摩尔。
4.根据权利要求1所述手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于钯催化剂选自双(二亚苄基丙酮)钯、三(二亚苄基丙酮)二钯、醋酸钯、烯丙基氯化钯二聚物、二乙腈二氯化钯、氯化钯、碘化钯、乙酰丙酮钯中的任意一种。
5.根据权利要求1所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于配体选自(S)-BINAP、(S)-SegPhos、(S)-SynPhos、(S)-MeO-BIPHEP、(S)-DTBM-Segphos、(S)-SDP、(S)-DiFluorPhos的任意一种。
6.根据权利要求1所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于银盐选自磷酸银、碳酸银、醋酸银、三氟甲磺酸银、四氟硼酸银、硝酸银的任意一种。
7.根据权利要求1所述手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于2-(2-碘芳氨基)环辛-1-烯-1-羧酸酯和钯催化剂、配体、银盐的摩尔比为1:0.1~0.4:0.1~0.4:1~5。
8.根据权利要求1所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于反应温度为40-80℃,反应时间为0.1-72h,优选为5h。
9.根据权利要求1所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于后处理步骤为:反应结束后,在冰浴条件下缓慢滴加乙酸及冰水混合液直至固体完全溶解,然后加入乙酸乙酯萃取水相三次,合并有机相,加入饱和食盐水洗涤,旋蒸除去溶剂后经柱层析分离得到目标产物,柱层析的流动相为体积比20~100:1的石油醚和乙酸乙酯混合物。
10.根据权利要求9所述的手性吲哚-2,3-并八元碳环化合物的制备方法,其特征在于于乙酸及冰水混合液中,乙酸及冰水的体积比为1:10-10:1,滴加速度为10-50滴/分钟。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011448322.4A CN112479982B (zh) | 2020-12-11 | 2020-12-11 | 一种手性吲哚-2,3-并八元碳环化合物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011448322.4A CN112479982B (zh) | 2020-12-11 | 2020-12-11 | 一种手性吲哚-2,3-并八元碳环化合物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112479982A true CN112479982A (zh) | 2021-03-12 |
CN112479982B CN112479982B (zh) | 2022-11-08 |
Family
ID=74941643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011448322.4A Active CN112479982B (zh) | 2020-12-11 | 2020-12-11 | 一种手性吲哚-2,3-并八元碳环化合物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112479982B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113121548A (zh) * | 2021-04-23 | 2021-07-16 | 青岛农业大学 | 一种吲哚并八元中环化合物及其制备方法 |
CN116041359A (zh) * | 2022-12-30 | 2023-05-02 | 成都大学 | 一种由钯催化构建的七元吲哚螺杂环类手性衍生物 |
-
2020
- 2020-12-11 CN CN202011448322.4A patent/CN112479982B/zh active Active
Non-Patent Citations (2)
Title |
---|
JUN MARUYAMA ET AL.: "Novel synthesis of fused indoles and 2-substituted indoles by the palladiumcatalyzed cyclization of N-cycloalkenyl-o-haloanilines", 《TETRAHEDRON》 * |
赵临襄 等: "《化学制药工艺学 第4版》", 31 August 2015, 中国医药科技出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113121548A (zh) * | 2021-04-23 | 2021-07-16 | 青岛农业大学 | 一种吲哚并八元中环化合物及其制备方法 |
CN116041359A (zh) * | 2022-12-30 | 2023-05-02 | 成都大学 | 一种由钯催化构建的七元吲哚螺杂环类手性衍生物 |
CN116041359B (zh) * | 2022-12-30 | 2025-03-04 | 成都大学 | 一种由钯催化构建的七元吲哚螺杂环类手性衍生物 |
Also Published As
Publication number | Publication date |
---|---|
CN112479982B (zh) | 2022-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5674059B2 (ja) | ルテニウム錯体を含む水素移動反応用触媒及び水素移動反応物の製造方法 | |
Chen et al. | Modular Chiral bisoxalamide–copper-catalyzed asymmetric Oxo-Diels–Alder reaction: carbonyl coordination for high enantio-and diastereocontrols | |
CN112479982A (zh) | 一种手性吲哚-2,3-并八元碳环化合物的制备方法 | |
CN112916042B (zh) | 基于四甲基螺二氢茚骨架的手性季铵盐相转移催化剂及制备方法 | |
CN104744394A (zh) | 一种不对称合成含三氟甲基手性季碳化合物的方法 | |
CN113980028A (zh) | 一种手性螺环吲哚酮类化合物的制备方法 | |
CN106242935B (zh) | 一种三芳基取代手性化合物的合成方法 | |
CN104086477B (zh) | 光学活性螺环戊烷‑1,3′‑吲哚及其衍生物的制备方法 | |
CN113754544B (zh) | 一种多取代(e)-三氟甲基烯烃的制备方法 | |
CN107721858B (zh) | 相转移催化β-酮酸酯不对称α-苯甲酰化的方法 | |
Nakano et al. | Polymer-supported chiral phosphinooxazolidine ligands for palladium-catalyzed asymmetric allylic alkylations and Diels–Alder reactions | |
JP5046213B2 (ja) | 光学活性アルコール化合物の製法 | |
CN112194559B (zh) | 一种手性及非手性2,2’-二卤代联芳基化合物的合成方法 | |
CN112675920B (zh) | 一类单手性中心催化剂及其制备和催化合成手性醇类化合物和手性α-烯丙醇的方法 | |
EP3609859B1 (en) | Chiral metal complex compounds | |
CN112279765A (zh) | 一种手性α-氟代酮化合物的制备方法 | |
CN110872232B (zh) | 相转移催化β-酮酸酯不对称α-二氟甲基化的方法 | |
MacLeod et al. | Synthesis of chiral 1, 3-disubstituted tetrahydroisoquinolines and their use in the asymmetric addition of diethylzinc to aldehydes | |
CN108101737B (zh) | 一种氢化萘结构单元的手性化合物的合成方法 | |
CN106588582B (zh) | 一种反式二苯乙烯类化合物的光催化合成方法 | |
JP6188066B2 (ja) | 光学活性非対称ビスインドール化合物及びその製造方法 | |
Yuan | Structural Implementation of Unsatured Systems Driven by Electrophilic Nitrogen-Containing Functional Groups. | |
CN106995377B (zh) | 仿生催化不对称氢化合成手性含氟炔丙胺衍生物的方法 | |
CN119569518A (zh) | 一种非活化烯烃的碳官能团化方法 | |
Andert | Palladium Catalyzed Suzuki-Miyaura Cross-Coupling of Axially Chiral Biaryls |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |